Effectiveness of risk minimisation measures for valproate: a drug utilisation study in Europe, analysis of data from Spain

被引:1
作者
Ehlken, Birgit [1 ]
Stevanovic, Irena [2 ]
Kaplan, Sigal [3 ]
Dresco, Isabelle [4 ]
Granados, Denis [5 ]
Toussi, Massoud [6 ]
机构
[1] IQVIA, Munich, Germany
[2] Sanofi, Barcelona, Spain
[3] Teva Pharmaceut Ind Ltd, Netanya, Israel
[4] Sanofi, Gentilly, France
[5] Sanofi R&D, Chilly Mazarin, France
[6] IQVIA, Courbevoie, France
关键词
Bipolar disorder; Drug utilisation study; Epilepsy; Risk minimisation measures; Valproate; Women of childbearing potential;
D O I
10.33588/rn.7311.2021247
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Introduction. Risk minimisation measures for valproate were implemented in Spain in 2015. Objective. The objective of this study is to assess the effectiveness of valproate risk minimisation measures in Spain intended to decrease the use of valproate as a first-line therapy, and to evaluate the prescribing patterns of valproate in women, including women of childbearing potential, in the pre- and post-implementation risk minimisation measures periods. Materials and methods. The prescribing patterns of valproate in females and women of childbearing potential before and after risk minimisation measures implementation were examined using the longitudinal patient data database, which includes patient information from two panels: primary care physicians and neurologists/psychiatrists. Primary endpoint was the proportion of initial valproate prescriptions with at least one medication related to the valproate indications before the valproate initiation date. Results. The proportion of incident valproate prescriptions with previous use of medication related to valproate indications was 78.0% (95% CI, 73.9%; 81.5%), and 78.2% (74.5%; 81.4%) in the main pre-and post-implementation periods in the primary care physician panel. The corresponding figures for women of childbearing potential were 79.6% (73.6%; 84.5%) and 75.5% (69.7%; 80.6%), respectively. The incidence rate of pregnancies exposed to valproate (per 1,000 person-years) in women of childbearing potential decreased from 17.4 the entire pre-implementation to 8.5 in the entire post-implementation periods. Conclusion. After the implementation of risk minimisation measures for valproate in Spain, no meaningful change in prescribing was observed regarding the proportion of valproate initiations preceded by prior medication related to valproate indications. The preventative measures recommended for use of valproate in women of childbearing potential should be considered.
引用
收藏
页码:373 / 382
页数:10
相关论文
共 14 条
[1]   A pharmacoepidemiological study of antiepileptic drug consumption (1992-2004) [J].
Abasolo-Osinaga, E. ;
Abecia-Inchaurregui, L. C. ;
Etxeandia-Ikobaltzeta, I. ;
Burgos-Alonso, N. ;
Garcia-del Pozo, J. .
REVISTA DE NEUROLOGIA, 2008, 46 (08) :449-453
[2]  
Bipolar Disorder Clinical Practice Working Group, 2012, GUIA PRACT CLIN TRAS
[3]   Valproate [J].
Bowden, CL .
BIPOLAR DISORDERS, 2003, 5 (03) :189-202
[4]  
EMA, NEW MEAS AV VALPR EX
[5]  
EMA, NEW REV VALPR US PRE
[6]  
European Network of Centres for Pharmacoepidemiology and Pharmacovigilance, EUR UN EL REG POST S
[7]  
Institute of Health Information, 2010, PRIM CAR INF SYST SI
[8]  
Lopez Gonzalez FJ, 2020, RECOMENDACIONES DIAG
[9]   The SANAD study of effectiveness of valproate, lamotrigine, or topiramate for generalised and unclassifiable epilepsy: an unblinded randomised controlled trial [J].
Marson, Anthony G. ;
Al-Kharusi, Asya M. ;
Alwaidh, Muna ;
Appleton, Richard ;
Baker, Gus A. ;
Chadwick, David W. ;
Cramp, Celia ;
Cockerell, Oliver C. ;
Cooper, Paul N. ;
Doughty, Julie ;
Eaton, Barbara ;
Gamble, Carrot ;
Goulding, Peter J. ;
Howell, Stephen J. L. ;
Hughes, Adrian ;
Jackson, Margaret ;
Jacoby, Ann ;
Kellett, Mark ;
Lawson, Geoffrey R. ;
Leach, John Paul ;
Nicolaides, Paola ;
Roberts, Richard ;
Shackley, Phil ;
Shen, Jing ;
Smith, David F. ;
Smith, Philip E. M. ;
Smith, Catrin Tudur ;
Vanoli, Alessandr A. ;
Williamson, Paula R. .
LANCET, 2007, 369 (9566) :1016-1026
[10]   Comparative study of antiepileptic drug use during pregnancy over a period of 12 years in Spain. Efficacy of the newer antiepileptic drugs lamotrigine, levetiracetam, and oxcarbazepine [J].
Martinez Ferri, M. ;
Pena Mayor, P. ;
Perez Lopez-Fraile, I. ;
Escartin Siquier, A. ;
Martin Moro, M. ;
Forcadas Berdusan, M. .
NEUROLOGIA, 2018, 33 (02) :78-84